Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 21;4(4):CD008708.
doi: 10.1002/14651858.CD008708.pub5.

Hematopoietic stem cell transplantation for people with β-thalassaemia

Akshay Sharma  1 , Vanitha A Jagannath  2 , Latika Puri  3
Affiliations

Hematopoietic stem cell transplantation for people with β-thalassaemia

Akshay Sharma et al. Cochrane Database Syst Rev. .

Abstract

Background: Thalassaemia is an autosomal recessive blood disorder, caused by mutations in globin genes or their regulatory regions, resulting in a reduced rate of synthesis of one of the globin chains that make up haemoglobin. In β-thalassaemia there is an underproduction of β-globin chains combined with excess of free α-globin chains. The excess free α-globin chains precipitate in red blood cells, leading to their increased destruction (haemolysis) and ineffective erythropoiesis. The conventional treatment is based on the correction of haemoglobin through regular red blood cell transfusions and treating the iron overload that develops subsequently with iron chelation therapy. Although, early detection and initiations of such supportive treatment has improved the quality of life for people with transfusion-dependent thalassaemia, allogeneic hematopoietic stem cell transplantation is the only widely available therapy with a curative potential. Gene therapy for β-thalassaemia has recently received conditional authorisation for marketing in Europe, and may soon become widely available as another alternative therapy with curative potential for people with transfusion-dependent thalassaemia. This is an update of a previously published Cochrane Review.

Objectives: To evaluate the effectiveness and safety of different types of hematopoietic stem cell transplantation, in people with transfusion-dependent β-thalassaemia.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also searched online trial registries. Date of the most recent search: 07 April 2021.

Selection criteria: Randomised controlled trials and quasi-randomised controlled trials comparing hematopoietic stem cell transplantation with each other or with standard therapy (regular transfusion and chelation regimen).

Data collection and analysis: Two review authors independently screened trials and had planned to extract data and assess risk of bias using standard Cochrane methodologies and assess the quality using GRADE approach, but no trials were identified for inclusion in the current review.

Main results: No relevant trials were retrieved after a comprehensive search of the literature.

Authors' conclusions: We were unable to identify any randomised controlled trials or quasi-randomised controlled trials on the effectiveness and safety of different types of hematopoietic stem cell transplantation in people with transfusion-dependent β-thalassaemia. The absence of high-level evidence for the effectiveness of these interventions emphasises the need for well-designed, adequately-powered, randomised controlled clinical trials.

PubMed Disclaimer

Conflict of interest statement

There are no financial conflicts of interest and the authors declare that they do not have any associations with any parties who may have vested interests in the results of this review.

AS is the principal investigator of a clinical trial for gene therapy of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics. The sponsor provides funding for the clinical trial which includes salary support paid to his institution. This is not related in any way to this work product. AS also has research collaboration with Novartis pharmaceuticals for their sickle cell gene therapy clinical trial for which he is not financially compensated in any way.

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Chandy 2005 {published data only}
    1. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005;36(10):839-45. [CFGD REGISTER: TH28e] [PMID: ] - PubMed
    1. Dennison D, Chandy M, Poonkuzhali B, Srivastava A, Shaji RV, Remington NEJ, et al. Plasma busulfan levels influence rejection in bone marrow transplantation for homozygous beta thalassaemia. Blood 1998;92(10 Suppl 1):127a. [CFGD REGISTER: TH28b]
    1. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Kanagasabapathy AS, Krishnamoorthy R. Correlation of hepatic glutathione S-transferase levels with busulfan pharmacokinetics in children with homozygous beta thalassemia undergoing bone marrow transplantation. Blood 1998;92(10 Suppl 1):128a. [CFGD REGISTER: TH28a]
    1. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metabolism and Disposition 2001;29(3):264-7. [CENTRAL: CN-01731482] [CFGD REGISTER: TH28f] [EMBASE: 32179525] [PMID: ] - PubMed
    1. Poonkuzhali B, Srivastava A, Quernin MH, Dennison D, Aigrain EJ, Kanagasabapathy AS, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;24(1):5-11. [CFGD REGISTER: TH28c] - PubMed
Dennison 2003 {published data only}
    1. Dennison JD, Quernin MH, Al Kindi S, Muralitharan S, Tauro M, Kanan K, et al. Oral versus intravenous busulfan in bone marrow transplantation for thalassemia. Blood 2003;102(11). [ABSTRACT NO.: 5581] [ABSTRACT NO.: 5581] [CFGD REGISTER: TH48]
Gaziev 1995 {published data only}
    1. Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, et al. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995;80(4):300-4. [CFGD REGISTER: TH10] [PMID: ] - PubMed
Irfan 2008 {published data only}
    1. Irfan M, Hashmi K, Adil S, Shamsi T, Farzana T, Ansari S, et al. Beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. Journal of the Pakistan Medical Association 2008;58(3):107-10. [CFGD REGISTER: TH157] [PMID: ] - PubMed

Additional references

Andreani 2011
    1. Andreani M, Testi M, Battarra M, Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011;2(1):21-2. [PMID: ] - PMC - PubMed
Angelucci 2014
    1. Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014;99(5):811-20. [PMID: ] - PMC - PubMed
Baronciani 2016
    1. Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016;51(4):536-41. [PMID: ] - PubMed
Borgna‐Pignatti 2004
    1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, DelVecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93. [PMID: ] - PubMed
Caocci 2011
    1. Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, et al. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17(6):861-6. [DOI: 10.1016/j.bbmt.2010.09.011] [PMID: ] - DOI - PubMed
Caocci 2017
    1. Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. American Journal of Hematology 2017;92(12):1303-10. [DOI: 10.1002/ajh.24898] [PMID: ] - DOI - PubMed
Cappellini 2014
    1. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 3rd edition. Nicosia, Cyprus: Thalassaemia International Federation, 2014. [ISBN-13: 978-9963-717-06-4] - PubMed
Cheuk 2008
    1. Cheuk DK, Mok AS, Lee AC, Chiang AK, Ha SY, Lau YL, et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant 2008;42(5):319-27. [DOI: 10.1038/bmt.2008.165] [PMID: ] - DOI - PubMed
Coquerelle 2019
    1. Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, et al. Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation. Hum Gene Ther 2019;30(6):753-61. [DOI: 10.1089/hum.2018.178] [PMID: ] - DOI - PubMed
Deeks 2011
    1. Deeks J, Higgins JP, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Di Bartolomeo 2008
    1. Di Bartolomeo P, Santarone S, Di Bartolomeo E, Olioso P, Bavaro P, Papalinetti G, et al. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. American Journal of Hematology 2008;83(7):528-30. [PMID: ] - PubMed
Dogramaci 2009
    1. Dogramaci AC, Savas N, Ozer B, Duran N. Skin diseases in patients with beta-thalassemia major. International Journal of Dermatology 2009;48(10):1057-61. - PubMed
Egger 1997
    1. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. - PMC - PubMed
EMA Zynteglo 2019
    1. European Medicines Agency. Zynteglo. www.ema.europa.eu/en/medicines/human/EPAR/zynteglo (accessed 20 April 2020).
Galambrun 2013
    1. Galambrun C, Pondarre C, Bertrand Y, Loundou A, Bordigoni P, Frange P, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 2013;19(1):62-8. [PMID: ] - PubMed
Ghavamzadeh 2013
    1. Ghavamzadeh A, Alimoghaddam K, Ghaffari F, Derakhshandeh R, Jalali A, Jahani M. Twenty years of experience on stem cell transplantation in Iran. Iranian Red Crescent medical journal 2013;15(2):93-100. [PMID: ] - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Hladun 2013
    1. Hladun R, Elorza I, Olive T, Dapena JL, Llort A, Sanchez de Toledo J, et al. Results of hematopoietic stem cell transplantation in hemoglobinopathies: thalassemia major and sickle cell disease [Resultados del trasplante de progenitores hematopoyeticos en hemoglobinopatias: talasemia maior y enfermedad drepanocitica.]. Anales de Pediatria 2013;79(2):75-82. [PMID: ] - PubMed
Hongeng 2006
    1. Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U, et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 2006;12(6):683-7. [PMID: ] - PubMed
Hussein 2013
    1. Hussein AA, Al-Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel-Rahman F, et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatric Blood & Cancer 2013;60(8):1345-9. [PMID: ] - PubMed
Iannone 2003
    1. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biology of Blood and Marrow Transplantation 2003;9(8):519-28. [PMID: ] - PubMed
Isgro 2010
    1. Isgro A, Gaziev J, Sodani P, Lucarelli G. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Annals of the New York Academy of Sciences 2010;1202:149-54. [PMID: ] - PubMed
Jacobsohn 2004
    1. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004;364(9429):156-62. [PMID: ] - PubMed
La Nasa 2005
    1. La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Annals of the New York Academy of Sciences 2005;1054:186-95. [PMID: ] - PubMed
La Nasa 2013
    1. La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 2013;122(13):2262-70. [PMID: ] - PubMed
Li 2012
    1. Li C, Wang Y, Wu X, Pei F, He Y, Feng X, et al. [Pretreatment doses of antithymocyte globubin-fresenius for allogeneic hematopoietic stem cell transplantation for beta-thalassemia major]. Journal of Southern Medical University 2012;32(5):691-4. [PMID: ] - PubMed
Locatelli 2013
    1. Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013;122(6):1072-8. [PMID: ] - PubMed
Lucarelli 1999
    1. Lucarelli G, Clift RA, Galimberti M, Angelucci E, Giardini C, Baronciani D, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999;93(4):1164-7. [PMID: ] - PubMed
Lucarelli 2008
    1. Lucarelli G. Advances in the allogeneic transplantation for thalassemia. Blood Reviews 2008;22(2):53-63. [PMID: ] - PubMed
Lucarelli 2012
    1. Lucarelli G, Isgro A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harbor perspectives in medicine 2012;2(5):a011825. [PMID: ] - PMC - PubMed
Modell 2008
    1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86(6):480-7. - PMC - PubMed
Olivieri 1999
    1. Olivieri NF. The beta-thalassemias. New England Journal of Medicine 1999;341(2):99-109. - PubMed
Oringanje 2020
    1. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No: CD007001. [DOI: 10.1002/14651858.CD007001.pub5] [PMID: ] - DOI - PubMed
Petersdorf 2004
    1. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Current Opinion in Hematology 2004;11(6):386-91. [PMID: ] - PubMed
Piel 2014
    1. Piel FB, Weatherall DJ. The α-thalassemias. N Engl J Med 2014;371(20):1908-16. [PMID: ] - PubMed
Rachmilewitz 2011
    1. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011;118(13):3479-88. [PMID: ] - PubMed
RevMan 2011 [Computer program]
    1. Review Manager (RevMan). Version 5.1. The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Sadelain 2005
    1. Sadelain M, Lisowski L, Samakoglu S, Rivella S, May C, Riviere I. Progress toward the genetic treatment of the beta-thalassemias. Annals of the New York Academy of Sciences 2005;1054:78-91. [PMID: ] - PubMed
Schrier 2005
    1. Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annual Review of Medicine 2005;56:157-71. - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shenoy 2017
    1. Shenoy S, Angelucci E, Arnold SD, Baker KS, Bhatia M, Bresters D, et al. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017;23(4):552-61. [DOI: 10.1016/j.bbmt.2017.01.009] [PMID: ] - DOI - PubMed
Sodani 2011
    1. Sodani P, Isgro A, Gaziev J, Paciaroni K, Marziali M, Simone MD, et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients. Pediatric Reports 2011;3 Suppl 2:e13. [PMID: ] - PMC - PubMed
Sruamsiri 2013
    1. Sruamsiri R, Chaiyakunapruk N, Pakakasama S, Sirireung S, Sripaiboonkij N, Bunworasate U, et al. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program. BMC Health Serv Res 2013;13:45. [PMID: ] - PMC - PubMed
Sterne 2011
    1. Sterne JA, Effer M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Taher 2013
    1. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. American Journal of Hematology 2013;88(5):409-15. [DOI: 10.1002/ajh.23405] [PMID: ] - DOI - PMC - PubMed
Thomas 1982
    1. Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P, et al. Marrow transplantation for thalassaemia. Lancet 1982;2(8292):227-9. [PMID: ] - PubMed
van Besien 2000
    1. Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone marrow transplantation 2000;26(4):445-9. [PMID: ] - PubMed
Weatherall 2001
    1. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nature Reviews Genetics 2001;2(4):245-55. [PMID: ] - PubMed
Weatherall 2002
    1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th edition. Oxford: Blackwell Science, 2002.
Weidlich 2016
    1. Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion 2016;56(5):1038-45. [DOI: 10.1111/trf.13513] [PMID: ] - DOI - PubMed

References to other published versions of this review

Jagannath 2011
    1. Jagannath VA, Fedorowicz Z, Al Hajeri A, Hu N, Sharma A. Hematopoietic stem cell transplantation for people with ß-thalassaemia major. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No: CD008708. [DOI: 10.1002/14651858.CD008708.pub2] - DOI - PubMed
Jagannath 2014
    1. Jagannath VA, Fedorowicz Z, Al Hajeri A, Sharma A. Hematopoietic stem cell transplantation for people with ß-thalassaemia major. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD008708. [DOI: 10.1002/14651858.CD008708.pub3] - DOI - PubMed
Jagannath 2016
    1. Jagannath VA, Fedorowicz Z, Al Hajeri A. Hematopoietic stem cell transplantation for people with ß‐thalassaemia major. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No: CD008708. [DOI: 10.1002/14651858.CD008708.pub4] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources